Aldevron Breakthrough Blog

Small-Scale. Big Impact.

July 30, 2025 by Deepika Bhargo

Empowering innovation with ssGMP

In the fast-paced world of genomic medicine, transformative therapies often begin with bold ideas, but not always with large-scale production needs. Early-stage innovators face numerous challenges, but accessing high-quality cGMP plasmid DNA should not be one of them. For those advancing early-phase programs, the need for reliable and scalable plasmid DNA at the right quantity is critical—and often underserved.

As part of our mission to be an engine of innovation for pioneers in genomic medicine, we recognize this growing demand among biotech startups, academic researchers, and early-stage drug developers for smaller, more agile, yet scalable solutions. These innovators do not need grams of plasmid DNA; they need just the right amount, delivered quickly and cost-effectively, without compromising quality.

Introducing ssGMP: Small-scale GMP Plasmid DNA
Our ssGMP service is purpose-built for clients who require smaller quantities of cGMP plasmid DNA—from 1 mg to 500 mg. It maintains the same high standards of quality and compliance as our large-scale offerings while bringing you these benefits:

The size you need, when you need it
One of the greatest advantages of our ssGMP service is its right-sized platform manufacturing process. This ensures you receive exactly the amount of cGMP plasmid DNA your program requires. By eliminating unnecessary volume, we help reduce costs, minimize waste, and accelerate timelines, all while providing these advantages:

Through our ssGMP service, you see an unwavering commitment to support innovation across the biotech development landscape. By making high-quality cGMP manufacturing more accessible and adaptable, you can be empowered to address the unmet needs of diverse therapeutic modalities now and into the future.

Subscribe to our blog

ABOUT THE AUTHOR

Deepika Bhargo

Deepika Bhargo is a senior product manager for plasmid DNA at Aldevron. She has bachelor's degrees in Quantitative Economics and Political Science from Tufts University, and an MBA from Dartmouth.